These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 19399381)

  • 21. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
    Otsuki M; Goya K; Kasayama S
    Vasc Health Risk Manag; 2005; 1(3):209-15. PubMed ID: 17319106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Is type-2 diabetes mellitus preventable?].
    Jermendy G
    Orv Hetil; 2003 Sep; 144(39):1909-17. PubMed ID: 14598569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventing macrovascular disease in patients with type 2 diabetes mellitus.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2003; 3(4):283-97. PubMed ID: 14728081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices.
    Kaul S; Stockbridge N; Butler J
    Circulation; 2020 Nov; 142(20):1974-1988. PubMed ID: 33196311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diabetes and coronary artery disease: not just a risk factor.
    Grant PJ; Cosentino F; Marx N
    Heart; 2020 Sep; 106(17):1357-1364. PubMed ID: 32499237
    [No Abstract]   [Full Text] [Related]  

  • 26. Risk Factor Control in Stroke Survivors with Diagnosed and Undiagnosed Diabetes: A Ghanaian Registry Analysis.
    Sarfo FS; Akassi J; Agyei M; Kontoh S; Ovbiagele B
    J Stroke Cerebrovasc Dis; 2020 Dec; 29(12):105304. PubMed ID: 32992189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological management of modifiable cardiovascular risk factors (blood pressure and lipids) following diagnosis of myocardial infarction, stroke and diabetes: comparison between population-based studies in Russia and Norway.
    Cook S; Hopstock LA; Eggen AE; Bates K; Iakunchykova O; Kontsevaya A; McKee M; Schirmer H; Voevoda M; Kudryavtsev AV; Malyutina S; Leon DA
    BMC Cardiovasc Disord; 2020 May; 20(1):234. PubMed ID: 32430002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
    Zinman B; Inzucchi SE; Lachin JM; Wanner C; Fitchett D; Kohler S; Mattheus M; Woerle HJ; Broedl UC; Johansen OE; Albers GW; Diener HC;
    Stroke; 2017 May; 48(5):1218-1225. PubMed ID: 28386035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Present recommendations in type 2 diabetes treatment.
    Lebovitz HE
    Endocrinol Nutr; 2009 Dec; 56 Suppl 4():46-9. PubMed ID: 20629232
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents.
    Saxon DR; Rasouli N; Eckel RH
    Drugs; 2018 Feb; 78(2):203-214. PubMed ID: 29305768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary prevention for stroke in the United Kingdom: results from the National Sentinel Audit of Stroke.
    Rudd AG; Lowe D; Hoffman A; Irwin P; Pearson M
    Age Ageing; 2004 May; 33(3):280-6. PubMed ID: 15082434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ischemic stroke in patients receiving aspirin.
    Pujol Lereis VA; Ameriso S; Povedano GP; Ameriso SF
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):868-72. PubMed ID: 21703876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.
    Basile J; Houston M; Ferrario CM
    J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795
    [No Abstract]   [Full Text] [Related]  

  • 34. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II.
    Beckman JA; Paneni F; Cosentino F; Creager MA
    Eur Heart J; 2013 Aug; 34(31):2444-52. PubMed ID: 23625211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review.
    Freeman JS; Gross B
    Expert Rev Clin Pharmacol; 2012 Jan; 5(1):31-42. PubMed ID: 22142157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical and lifestyle management of peripheral arterial disease.
    Parvar SL; Fitridge R; Dawson J; Nicholls SJ
    J Vasc Surg; 2018 Nov; 68(5):1595-1606. PubMed ID: 30360849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controversies: Stroke Prevention in Chronic Kidney Disease.
    Lau WL
    J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105679. PubMed ID: 33640261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing the risk of stroke through appropriate targets and treatments.
    Davidson MH; Basile J; Garber AJ; Phillips RA
    Prev Cardiol; 2007; 10(4):215-21. PubMed ID: 17917519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reducing cardiovascular disease risk in patients with diabetes: a message from the National Diabetes Education Program.
    Blonde L; Dempster J; Gallivan JM; Warren-Boulton E
    J Am Acad Nurse Pract; 2006 Nov; 18(11):524-33. PubMed ID: 17064330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug treatments in the secondary prevention of ischaemic stroke.
    Schulz UG
    Maturitas; 2013 Nov; 76(3):267-71. PubMed ID: 23769546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.